Lys321
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys321  -  p73 (human)

Site Information
ALNESSAkNGAASkR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 460605

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:
bone cancer ( 2 ) , colorectal cancer ( 2 ) , colorectal carcinoma ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , HCT116 (intestinal) ( 2 ) , liver ( 1 ) , Saos-2 (bone cell) ( 2 )

Upstream Regulation
Regulatory protein:
Abl (human) ( 2 ) , CBP (human) ( 2 ) , PCAF (human) ( 2 )
Treatments:
adriamycin ( 2 ) , LysCoA ( 2 )

Downstream Regulation
Effects of modification on p73:
molecular association, regulation ( 2 )
Effects of modification on biological processes:
apoptosis, induced ( 2 ) , cell growth, inhibited ( 2 ) , transcription, induced ( 2 )
Induce interaction with:
DNA ( 2 )

References 

1

Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4
20167786   Curated Info

2

Costanzo A, et al. (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9, 175-86
11804596   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.